Osimertinib (a third-generation EGFR-TKI) demonstrated better drug-toxicity profiles than first- and second-generation EGFR-TKIs in trials, and their efficacies in patients with advanced or metastatic NSCLC with secondary T790M mutation and EGFR-TKI resistance are encouraging [20]. Here, EGFR is linked to non-small cell lung carcinoma.